BioCentury | Jan 30, 2021
Distillery Therapeutics

Targeting the RAGE-LCP2 interaction for sepsis

...2021doi:10.1038/s41467-020-20577-3CONTACT: Timothy R. Billiar, University of Pittsburgh School of Medicine, Pittsburgh, Pa.email: billiartr@upmc.eduCONTACT: Yong Jiang, Southern Medical University, Guangzhou, Chinaemail: jiang48231@163.com Claire Quang Southern Medical University University...
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

...S.A.S. Toll interacting protein (TOLLIP) Colorectal cancer Mouse Inhibiting TOLLIP could help treat colon cancer. Southern Medical University...
BioCentury | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

...BCIQ: BioCentury Online Intelligence; ClinicalTrials.gov Target Company Product Lead Indication Status CAR Ganglioside GD2 (GD2) Southern Medical University...
BioCentury | Dec 19, 2018
Distillery Therapeutics

Musculoskeletal

...published online Nov. 26, 2018 doi:10.1073/pnas.1813000115 CONTACT: Xiaochun Bai, The Third Affiliated Hospital of Southern Medical University...
BioCentury | Dec 1, 2018
Product Development

Cell therapy momentum at ASH

...CD38, CD70 (CD27L) or prostate-specific membrane antigen (PSMA; FOLH1; GCPII) CAR Lymphomas Phase I/II 225 Southern Medical University...
BioCentury | Jul 10, 2018
Distillery Therapeutics

Cancer

...doi:10.1038/s41467-018-04999-8 CONTACT: Yongsheng Li, Third Military Medical University, Chongqing, China email: yli@tmmu.edu.cn CONTACT: Wei Yang, Southern Medical University...
BioCentury | Jun 2, 2018
Product Development

Breaking from the herd

...highly expressed in advanced NSCLC; knockdown suppresses epithelial-mesenchymal transition and decreases proliferation, migration and invasion Southern Medical University...
BioCentury | Jun 3, 2017
Product Development

Leading with lung

...are long non-coding RNAs (lncRNAs). An electronic abstract submitted by researchers at Nanfang Hospital and Southern Medical University...
...epirubicin, EIF3J-AS1 inhibition decreased autophagy and increased sensitivity to oxaliplatin and epirubicin Nanfang Hospital ; Southern Medical University...
...York, N.Y. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Southern Illinois University School of Medicine, Springfield, Ill. Southern Medical University...
BioCentury | Apr 28, 2016
Distillery Therapeutics

Therapeutics: microRNA-3188 (MIR3188); forkhead box O1 (FOXO1)

...Zhao, M. et al. Nat. Commun.; published online Apr. 20, 2016 doi:10.1038/ncomms11309 CONTACT: Weiyi Fang, Southern Medical University...
BioCentury | May 30, 2013
Distillery Therapeutics

Indication: Neurology

...Cao, X. et al. Nat. Med.; published online May 5, 2013; doi:10.1038/nm.3162 Contact: Tian-Ming Gao, Southern Medical University...
Items per page:
1 - 10 of 10
BioCentury | Jan 30, 2021
Distillery Therapeutics

Targeting the RAGE-LCP2 interaction for sepsis

...2021doi:10.1038/s41467-020-20577-3CONTACT: Timothy R. Billiar, University of Pittsburgh School of Medicine, Pittsburgh, Pa.email: billiartr@upmc.eduCONTACT: Yong Jiang, Southern Medical University, Guangzhou, Chinaemail: jiang48231@163.com Claire Quang Southern Medical University University...
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

...S.A.S. Toll interacting protein (TOLLIP) Colorectal cancer Mouse Inhibiting TOLLIP could help treat colon cancer. Southern Medical University...
BioCentury | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

...BCIQ: BioCentury Online Intelligence; ClinicalTrials.gov Target Company Product Lead Indication Status CAR Ganglioside GD2 (GD2) Southern Medical University...
BioCentury | Dec 19, 2018
Distillery Therapeutics

Musculoskeletal

...published online Nov. 26, 2018 doi:10.1073/pnas.1813000115 CONTACT: Xiaochun Bai, The Third Affiliated Hospital of Southern Medical University...
BioCentury | Dec 1, 2018
Product Development

Cell therapy momentum at ASH

...CD38, CD70 (CD27L) or prostate-specific membrane antigen (PSMA; FOLH1; GCPII) CAR Lymphomas Phase I/II 225 Southern Medical University...
BioCentury | Jul 10, 2018
Distillery Therapeutics

Cancer

...doi:10.1038/s41467-018-04999-8 CONTACT: Yongsheng Li, Third Military Medical University, Chongqing, China email: yli@tmmu.edu.cn CONTACT: Wei Yang, Southern Medical University...
BioCentury | Jun 2, 2018
Product Development

Breaking from the herd

...highly expressed in advanced NSCLC; knockdown suppresses epithelial-mesenchymal transition and decreases proliferation, migration and invasion Southern Medical University...
BioCentury | Jun 3, 2017
Product Development

Leading with lung

...are long non-coding RNAs (lncRNAs). An electronic abstract submitted by researchers at Nanfang Hospital and Southern Medical University...
...epirubicin, EIF3J-AS1 inhibition decreased autophagy and increased sensitivity to oxaliplatin and epirubicin Nanfang Hospital ; Southern Medical University...
...York, N.Y. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Southern Illinois University School of Medicine, Springfield, Ill. Southern Medical University...
BioCentury | Apr 28, 2016
Distillery Therapeutics

Therapeutics: microRNA-3188 (MIR3188); forkhead box O1 (FOXO1)

...Zhao, M. et al. Nat. Commun.; published online Apr. 20, 2016 doi:10.1038/ncomms11309 CONTACT: Weiyi Fang, Southern Medical University...
BioCentury | May 30, 2013
Distillery Therapeutics

Indication: Neurology

...Cao, X. et al. Nat. Med.; published online May 5, 2013; doi:10.1038/nm.3162 Contact: Tian-Ming Gao, Southern Medical University...
Items per page:
1 - 10 of 10